Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 9:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 130 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Intranasal Oxytocin Clear all
Completed Not applicable Interventional Results available

Effect of Oxytocin on Craving and Therapy Response

NCT01827332
View directory record Official record
Conditions
Marijuana Dependence
Interventions
Oxytocin, Saline
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 1, 2017 · Synced Sep 4, 2026, 9:55 AM EDT
Completed Phase 3 Interventional Results available

A Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder

NCT02985749
View directory record Official record
Conditions
Autism Spectrum Disorder, Pervasive Developmental Disorder, ASD, PDD
Interventions
Intranasal Oxytocin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
12 Years to 55 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 30, 2024 · Synced Sep 4, 2026, 9:55 AM EDT
Completed Not applicable Interventional Results available

Oxytocin Treatment of Schizophrenia

NCT01028677
View directory record Official record
Conditions
Paranoia, Schizophrenia, Schizoaffective Disorder
Interventions
intranasal spray with oxytocin, nasal spray without oxytocin
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Sep 4, 2026, 9:55 AM EDT
Terminated Phase 1Phase 2 Interventional

Dose Response Relationship of Oxytocin on Irritability in Youths

NCT03863288
View directory record Official record
Conditions
Irritable Mood
Interventions
Functional MRI (fMRI), Oxytocin Intranasal Spray 8 International Unit (8IU), Oxytocin intranasal spray 24 International Unit (24IU), Oxytocin intranasal spray 48 International Unit (48IU), Oxytocin intranasal spray 80 International Unit (80IU), Placebo
Procedure · Drug
Lead sponsor
University of Nebraska
Other
Eligibility
14 Years to 18 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Sep 4, 2026, 9:55 AM EDT
Terminated Phase 1Phase 2 Interventional

Daily Intranasal Oxytocin for Childhood-Onset Schizophrenia

NCT01712646
View directory record Official record
Conditions
Childhood Onset Psychotic Disorders, Schizophrenia
Interventions
Intranasal Oxytocin
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
10 Years to 99 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Sep 4, 2026, 9:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Intranasal Neuropeptide on Emotion Perception in Trait Anxiety

NCT01551303
View directory record Official record
Conditions
Social Intelligence
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 29, 2014 · Synced Sep 4, 2026, 9:55 AM EDT
Completed Phase 2 Interventional Results available

Single Dose Intranasal Oxytocin and Cognitive Effects in Autism

NCT02493426
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
Intranasal Oxytocin, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
5 Years to 40 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 22, 2023 · Synced Sep 4, 2026, 9:55 AM EDT
Completed Not applicable Interventional Results available

Effect of Oxytocin on Stress in Marijuana Users

NCT01335789
View directory record Official record
Conditions
Marijuana Dependence
Interventions
Oxytocin, Saline
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 13, 2015 · Synced Sep 4, 2026, 9:55 AM EDT
Recruiting Phase 1 Interventional

Benefits of Oxytocin in Obstructive Sleep Apnea (OSA) Patients Using Continuous Positive Airway Pressure (CPAP) Machine

NCT03860233
View directory record Official record
Conditions
Sleep Apnea, Sleep Apnea, Obstructive
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
Vivek Jain
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 4, 2026, 9:55 AM EDT
Completed Phase 2 Interventional Results available

Intranasal Oxytocin Treatment for Social Deficits in Children With Autism

NCT01624194
View directory record Official record
Conditions
Autism
Interventions
Oxytocin nasal spray, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
6 Years to 12 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2019 · Synced Sep 4, 2026, 9:55 AM EDT
Terminated Phase 2 Interventional Results available

A Pharmaco-imaging Approach to Predicting Social Functioning and Clinical Responses to Oxytocin Administration in Schizophrenia

NCT03900754
View directory record Official record
Conditions
Schizophrenia
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
San Francisco, California • West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Sep 4, 2026, 9:55 AM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

The Effect of Oxytocin Administration on Interpersonal Cooperation in Borderline Personality Disorder Patients and Healthy Adults

NCT02225600
View directory record Official record
Conditions
Borderline Personality Disorder
Interventions
40 IU Intranasal Oxytocin, Placebo, 24 IU intranasal Oxytocin
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 4, 2026, 9:55 AM EDT
Terminated Not applicable Interventional Results available

Oxytocin Add on Study for Stable Schizophrenic Patients

NCT00506909
View directory record Official record
Conditions
Schizophrenia
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
David Feifel
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Sep 4, 2026, 9:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Pharmacokinetic Study of Intravenous and Intranasal Oxytocin in Healthy Subjects

NCT05672667
View directory record Official record
Conditions
Healthy Volunteer Study
Interventions
intravenous oxytocin, intranasal oxytocin
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 16, 2025 · Synced Sep 4, 2026, 9:55 AM EDT
Completed Phase 2 Interventional Results available

Intranasal Oxytocin and Learning in Autism

NCT01417026
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
Intranasal Oxytocin (Trade name: Syntocinon)
Drug
Lead sponsor
Robert Schultz
Other
Eligibility
12 Years to 17 Years · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Sep 4, 2026, 9:55 AM EDT
Completed Phase 4 Interventional Results available

Effects of Intranasal Oxytocin on Satiety Signaling in People With Schizophrenia

NCT01614093
View directory record Official record
Conditions
Schizophrenia
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 54 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 4, 2026, 9:55 AM EDT
Completed Phase 2 Interventional Results available

Oxytocin vs. Placebo for the Treatment Hyperphagia in Children and Adolescents With Prader-Willi Syndrome

NCT02629991
View directory record Official record
Conditions
Prader-Willi Syndrome, Hyperphagia
Interventions
Intranasal Oxytocin (IN-OXT), Matched Placebo
Drug · Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
5 Years to 18 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Sep 4, 2026, 9:55 AM EDT
Withdrawn Phase 2 Interventional

Oxytocin on Approach Bias and Craving

NCT03865615
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
Jennifer Mitchell
Other
Eligibility
21 Years to 40 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2022 · Synced Sep 4, 2026, 9:55 AM EDT
Completed Phase 2 Interventional Results available

Oxytocin and Social Cognition in Schizophrenia

NCT00884897
View directory record Official record
Conditions
Social Cognition, Social Anxiety, Emotional Intelligence
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Sep 4, 2026, 9:55 AM EDT
Completed Phase 4 Interventional Results available

Effects of Oxytocin on Behavior and Physiology in a Psychotherapy Setting

NCT01081249
View directory record Official record
Conditions
Behavior, Anxiety
Interventions
Placebo then intranasal oxytocin, Intranasal oxytocin then placebo
Drug
Lead sponsor
MacDonald, Kai, M.D.
Individual
Eligibility
18 Years to 65 Years · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Sep 4, 2026, 9:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Biological Basis of Individual Variation in Social Cooperation

NCT01566539
View directory record Official record
Conditions
Healthy
Interventions
Intranasal Oxytocin (OT) 24 IU, Intranasal Vasopressin (AVP), Intranasal Placebo, Intranasal Vasopressin (AVP) 40 IU, Lorazepam
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 30 Years
Enrollment
707 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2016
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 24, 2017 · Synced Sep 4, 2026, 9:55 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Intranasal Oxytocin for Infants With Prader-Willi Syndrome

NCT03245762
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
1 Week to 6 Months
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Sep 4, 2026, 9:55 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Oxytocin and the Social Brain

NCT02393456
View directory record Official record
Conditions
Social Psychology
Interventions
Intranasal oxytocin, Intranasal placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 30 Years
Enrollment
161 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Sep 4, 2026, 9:55 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Intranasal Oxytocin Administration and the Neural Correlates of Social and Non-Social Visual Perception

NCT02238379
View directory record Official record
Conditions
Social Perception
Interventions
Oxytocin, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Sep 4, 2026, 9:55 AM EDT